Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 11/20 | 0.60 |
| ▸ | MMP9 | P14780 | 8/20 | 0.55 |
| ▸ | MMP2 | P08253 | 7/20 | 0.55 |
| ▸ | MMP13 | P45452 | 6/20 | 0.55 |
| ▸ | MMP8 | P22894 | 3/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861635 | 1.00 | BMP1 (0.60) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2856295 | 0.93 | BMP1 (0.54) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2856298 | 0.93 | BMP1 (0.54) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2853983 | 0.91 | MMP2 (0.55) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2853988 | 0.91 | MMP2 (0.53) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2853986 | 0.91 | MMP2 (0.53) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2853979 | 0.91 | MMP2 (0.55) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2858317 | 0.89 | BMP1 (0.58) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL2858314 | 0.89 | BMP1 (0.58) | BMP1MMP9MMP2MMP13MMP8 | |
| SCHEMBL7346338 | 0.88 | BMP1 (0.65) | BMP1MMP9MMP2MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | claimed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | claimed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | claimed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | claimed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | claimed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |